The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells
The incidence of treatment-related neuroendocrine (NE) prostate cancer (t-NEPC) is rising as more potent drugs targeting the androgen signaling axis are clinically implemented. Neuroendocrine transdifferentiation (NEtD), an putative initial step in t-NEPC development, is induced by androgen deprivat...
| Κύριοι συγγραφείς: | , , , , , , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
American Association of Cancer Research
2019
|